SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : momo-T/FIF
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: John Metcalf who wrote (3559)11/17/2005 9:40:59 AM
From: tom pope  Read Replies (1) of 12215
 
ML's prospective view of TELK's short term catalysts is pretty glum. That makes its current strength all the more interesting.

3Q earnings non-event, Telcyta data expected
1H06
NEUTRAL
Volatility Risk:
HIGH

UPCOMING CATALYSTS: Data for all Phase III Telcyta ASSIST trials may become
available 1H06. As a reminder, ASSIST-1 tests Telcyta in 3rd-line ovarian cancer,
ASSIST-2 - 3rd-line lung cancer, and ASSIST-3 - 2nd-line ovarian cancer. Timing of
data availability for ASSIST-3 depend on completion of trial enrollment by YE05. Final
Phase II data for Telintra in MDS will be presented at the American Society of
Hematology (ASH) meeting in December 2005.
• ADJUSTING ESTIMATES ON TIMING OF POTENTIAL TELCYTA LAUNCH:
We adjusted our 2006 and 2007 EPS estimates based on timing of potential Telcyta
commercialization. Our 2006 EPS estimate declines to a loss of $1.12 from a loss of
$0.17, while our 2007 EPS estimate declines to a loss of $0.90 from a gain of $0.45

Reason for Report: Earnings Revision
.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News